R
Rifca Le Dieu
Researcher at Queen Mary University of London
Publications - 13
Citations - 1030
Rifca Le Dieu is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Chronic lymphocytic leukemia & Leukemia. The author has an hindex of 8, co-authored 13 publications receiving 935 citations. Previous affiliations of Rifca Le Dieu include University of London & Imperial College London.
Papers
More filters
Journal ArticleDOI
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
Alan G. Ramsay,Amy J. Johnson,Abigail M. Lee,Gullu Gorgun,Rifca Le Dieu,William Blum,John C. Byrd,John G. Gribben,John G. Gribben +8 more
TL;DR: Impaired actin polymerization results in CD4+ and CD8+ T cells from patients with chronic lymphocytic leukemia exhibiting defective immunological synapse formation with APCs is demonstrated and repair of immune synapse defects is identified as an essential step in improving cancer immunotherapy approaches.
Journal ArticleDOI
Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts.
Rifca Le Dieu,David Taussig,Alan G. Ramsay,Richard Mitter,Faridah Miraki-Moud,Rewas Fatah,Abigail M. Lee,T. Andrew Lister,John G. Gribben +8 more
TL;DR: T-cell dysfunction in AML is identified that may contribute to the failure of a host immune response against leukemic blasts.
Journal ArticleDOI
Eμ-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction
Gullu Gorgun,Alan G. Ramsay,Tobias A. W. Holderried,David Zahrieh,Rifca Le Dieu,Fenglong Liu,John Quackenbush,Carlo M. Croce,John G. Gribben +8 more
TL;DR: The utility of this animal model of CLL is demonstrated and it is defined as a versatile model to investigate both the molecular mechanisms of cancer-induced immune suppression and immunotherapeutic repair strategies.
Journal ArticleDOI
Clinical outcome of coronavirus disease 2019 in haemato-oncology patients.
James Aries,James Aries,Jeff K. Davies,Jeff K. Davies,Rebecca Auer,Simon Hallam,Silvia Montoto,Matthew Smith,Belen Sevillano,Vanessa Foggo,Bela Wrench,Bela Wrench,Krzysztof Zegocki,Samir G. Agrawal,Rifca Le Dieu,Rifca Le Dieu,Edward Truelove,Edward Truelove,Thomas Erblich,Thomas Erblich,Shamzah Araf,Shamzah Araf,Jessica Okosun,Jessica Okosun,Heather Oakervee,Jamie Cavenagh,John G. Gribben,John G. Gribben,John Riches,John Riches,John Riches +30 more
TL;DR: Patients with haematological malignancies are expected to be at increased risk of adverse outcomes from this viral infection, due being immunosuppressed as a consequence of the underlying cancer, and from the effects of therapy.
Journal ArticleDOI
MicroRNAs hsa-miR-99b, hsa-miR-330, hsa-miR-126 and hsa-miR-30c: Potential Diagnostic Biomarkers in Natural Killer (NK) Cells of Patients with Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME)
Robert D. Petty,Robert D. Petty,Neil E. McCarthy,Rifca Le Dieu,Jonathan R. Kerr,Jonathan R. Kerr +5 more
TL;DR: Altered microRNA expression in the peripheral blood mononuclear cells of CFS/ME patients are demonstrated, which are potential diagnostic biomarkers.